AVXL Stock Forecast 2025-2026
Distance to AVXL Price Targets
AVXL Price Momentum
10 Quality Stocks Worth Considering Now
Researching Anavex (AVXL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AVXL and similar high-potential opportunities.
Latest AVXL Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, AVXL has a bullish consensus with a median price target of $42.00 (ranging from $15.00 to $46.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $9.43, the median forecast implies a 345.4% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 387.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AVXL Analyst Ratings
AVXL Price Target Range
Latest AVXL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AVXL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 18, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Feb 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Jan 28, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Jan 28, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Jan 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Jan 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Jan 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Dec 26, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $42.00 |
| Dec 23, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Nov 27, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $40.00 |
| Nov 26, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Nov 25, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $40.00 |
| Oct 31, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $46.00 |
| Oct 18, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $40.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $40.00 |
| Jul 29, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $46.00 |
| Jul 22, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $46.00 |
| Jun 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $40.00 |
| May 10, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $40.00 |
Anavex Life Sciences Corp. (AVXL) Competitors
The following stocks are similar to Anavex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Anavex Life Sciences Corp. (AVXL) Financial Data
Anavex Life Sciences Corp. has a market capitalization of $802.16M with a P/E ratio of -18.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -37.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Anavex Life Sciences Corp. (AVXL) Business Model
About Anavex Life Sciences Corp.
Develops therapies for neurodegenerative diseases.
Anavex Life Sciences focuses on researching and developing novel compounds to treat neurodegenerative and central nervous system diseases, particularly through the use of sigma-1 receptor agonists. The company generates revenue by advancing its drug candidates through clinical trials and eventually bringing them to market, addressing significant unmet medical needs in the healthcare sector.
Anavex's focus on complex neurological conditions positions it as a key player in the biotechnology and healthcare industries. The company's research initiatives and partnerships are crucial for attracting investment and facilitating the development of new treatments that aim to improve patients' quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
42
CEO
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Country
United States
IPO Year
2015
Website
www.anavex.comAnavex Life Sciences Corp. (AVXL) Latest News & Analysis
Anavex Life Sciences Corp. (Nasdaq: AVXL) will present at the TD Cowen Health Care Conference on March 3, 2025, focusing on its treatments for CNS disorders. CEO Christopher U Missling will speak at 9:50 AM ET.
Anavex's presentation at a major healthcare conference could attract investor interest and boost stock prices, highlighting its focus on CNS disorders and innovative treatment developments.
Anavex Life Sciences Corp. (NASDAQ:AVXL) will host its Q1 2025 earnings conference call on February 12, 2025, at 8:30 AM ET. Participants include CEO Christopher Missling and CFO Sandra Boenisch.
Anavex Life Sciences' earnings call offers insights into financial performance and future outlook, critical for assessing investment potential and market position.
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
1 month agoThe company will host a webcast today at 8:30 a.m. Eastern Time, which may provide important updates for investors.
The webcast may provide key updates on company performance, strategy, or financials, influencing stock prices and investor sentiment.
Anavex Life Sciences expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's by late 2025. The Alzheimer's market could reach $15.5 billion by 2031. Phase 2 data on schizophrenia treatment is also due in 2025.
Anavex's anticipated EMA feedback on blarcamesine and the growing Alzheimer's market could significantly impact its valuation and investor sentiment, especially with phase 2 schizophrenia data due in 2025.
Anavex Life Sciences' stock rose 50% after EMA accepted blarcamesine for Alzheimer's review. The company has a $720M market cap and 8–10 quarters of cash runway.
Anavex's stock surge reflects optimism around blarcamesine's potential in Alzheimer's treatment, influencing market cap and cash runway, crucial for ongoing R&D and investor sentiment.
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
1 month agoA webcast and conference call is scheduled for February 12, 2025, at 8:30 am ET.
The scheduled webcast and conference call may indicate an upcoming financial update or earnings report, which can impact stock prices and investor sentiment.
Frequently Asked Questions About AVXL Stock
What is Anavex Life Sciences Corp.'s (AVXL) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Anavex Life Sciences Corp. (AVXL) has a median price target of $42.00. The highest price target is $46.00 and the lowest is $15.00.
Is AVXL stock a good investment in 2025?
According to current analyst ratings, AVXL has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.43. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AVXL stock?
Wall Street analysts predict AVXL stock could reach $42.00 in the next 12 months. This represents a 345.4% increase from the current price of $9.43. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Anavex Life Sciences Corp.'s business model?
Anavex Life Sciences focuses on researching and developing novel compounds to treat neurodegenerative and central nervous system diseases, particularly through the use of sigma-1 receptor agonists. The company generates revenue by advancing its drug candidates through clinical trials and eventually bringing them to market, addressing significant unmet medical needs in the healthcare sector.
What is the highest forecasted price for AVXL Anavex Life Sciences Corp.?
The highest price target for AVXL is $46.00 from Jason Kolbert at D. Boral Capital, which represents a 387.8% increase from the current price of $9.43.
What is the lowest forecasted price for AVXL Anavex Life Sciences Corp.?
The lowest price target for AVXL is $15.00 from at , which represents a 59.1% increase from the current price of $9.43.
What is the overall AVXL consensus from analysts for Anavex Life Sciences Corp.?
The overall analyst consensus for AVXL is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $42.00.
How accurate are AVXL stock price projections?
Stock price projections, including those for Anavex Life Sciences Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
